Pharmanest utilizes its proprietary technology, FibroNest, which is an advanced AI-driven digital pathology image analysis method designed for the high-resolution quantification of fibrosis phenotypes and associated inflammation. This innovative approach allows for the automated analysis of digital images from stained tissue slides, providing detailed insights into fibrotic conditions across various tissues, including liver, lung, kidney, and skin. FibroNest has been validated through extensive research, including 9 Phase 2 studies and 2 Phase 3 studies, and is compatible with a wide range of digital imaging modalities, making it a versatile tool for both clinical and pre-clinical pharmaceutical drug development projects.

The technology behind FibroNest emphasizes its translational capabilities, allowing for consistent application from discovery through clinical development. It is designed to generate robust and continuous scores that quantify the severity and progression of fibrosis, thereby facilitating a deeper understanding of fibrotic diseases. The quantification process is meticulously calibrated and validated in collaboration with pathologists, ensuring accuracy and reliability in the analysis of various fibrotic conditions. This comprehensive approach positions Pharmanest as a leader in the field of digital pathology and fibrosis research, with a commitment to advancing therapeutic strategies through innovative imaging technologies.

United States

PharmaNest is an image analysis and contract research company focused in the development and validation of novel standards for the quantification of Fibrosis for drug discovery and development.

Pharmanest

Company Details